On Friday, Relmada Therapeutics Inc (NASDAQ: RLMD) opened higher 3.92% from the last session, before settling in for the closing price of $0.72. Price fluctuations for RLMD have ranged from $0.24 to $4.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 27.17% at the time writing. With a float of $26.73 million, this company’s outstanding shares have now reached $33.19 million.
The firm has a total of 17 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relmada Therapeutics Inc is 19.46%, while institutional ownership is 25.06%. The most recent insider transaction that took place on May 16 ’25, was worth 86,060. In this transaction Chief Operating Officer of this company bought 200,000 shares at a rate of $0.43, taking the stock ownership to the 412,295 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Financial Officer bought 90,000 for $0.49, making the entire transaction worth $43,686. This insider now owns 228,335 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.28% during the next five years compared to 0.68% growth over the previous five years of trading.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Check out the current performance indicators for Relmada Therapeutics Inc (RLMD). In the past quarter, the stock posted a quick ratio of 5.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Analysing the last 5-days average volume posted by the [Relmada Therapeutics Inc, RLMD], we can find that recorded value of 0.77 million was lower than the volume posted last year of 1.62 million. As of the previous 9 days, the stock’s Stochastic %D was 93.57%. Additionally, its Average True Range was 0.09.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 96.42%, which indicates a significant increase from 95.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.16% in the past 14 days, which was lower than the 170.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4040, while its 200-day Moving Average is $1.4688. Now, the first resistance to watch is $0.7819. This is followed by the second major resistance level at $0.8139. The third major resistance level sits at $0.8588. If the price goes on to break the first support level at $0.7050, it is likely to go to the next support level at $0.6601. Now, if the price goes above the second support level, the third support stands at $0.6281.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are currently 33,192K shares outstanding in the company with a market cap of 24.89 million. Presently, the company’s annual sales total 0 K according to its annual income of -79,980 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -17,560 K.
